Cancer Research UK Joins ACRP Standards Group
Cancer Research UK has become a member of the Workforce Development Steering Committee of the Association of Clinical Research Professionals (ACRP).
Cancer Research UK has become a member of the Workforce Development Steering Committee of the Association of Clinical Research Professionals (ACRP).
The group’s main goal is to review and approve core competence standards for clinical research professionals. Its members comprise industry and academic organizations across the global clinical research sector.
"Cancer Research UK has long supported the training and development of the next generation of clinical research professionals," says Dr. Nigel Blackburn, Cancer Research UK's director of drug development. "We're really pleased that we now have the opportunity to contribute to this international collaboration led by ACRP which will help to maintain a high quality in clinical research across the globe."
As its first initiative, the committee will request public comment on a competence framework for clinical research associates (CRAs). This framework will define standards for clinical trial monitors/CRAs within the eight core competence domains for clinical research professionals, as defined by the Joint Task Force for Clinical Trial Competence.
"ACRP is excited to announce Cancer Research UK as a member of the ACRP Workforce Development Steering Committee," says Terri Hinkley, RN, BScN, MBA, CCRC, FACRP, ACRP's Workforce Innovation Officer. "We are thankful for Cancer Research UK's willingness to support workforce competence standardization as a means of promoting excellence in clinical research.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
